XLO today
$8.24-$0.23 (-2.72%)close Nov 12, 2026Trend
DailyDowntrend (confirmed)
4 hourExpanding
1 hourStrong Bearish
15 minBearish
5 minStrong Bullish
Daily trend turns up above $19.32
Key levels
Resistance$9.00
Resistance$8.33
Support$7.05
Latest news & SEC filings
EarningsXilio Therapeutics Posts Q3 2026 Results, Gives Pipeline Update
EarningsXilio Therapeutics posts smaller Q3 loss, revenue above estimates
SEC FilingXilio Therapeutics, Inc. filed a report on a major company event (Form 8-K)
All XLO news →About Xilio Therapeutics
Xilio Therapeutics is a clinical-stage biotechnology company that creates cancer immunotherapies engineered to become active only inside tumors. Its pipeline includes an IL-12 candidate, a dual-targeting antibody-cytokine fusion protein, and T cell engagers aimed at solid tumors. The company works with AbbVie and Gilead through collaboration and license agreements and is based in the United States.
Based on the company's 10-K filed Mar 23, 2026.
Nasdaq · Healthcare
Xilio Therapeutics, Inc. (XLO)
What Is the Price Target for XLO?
SEPT Low Target
$16.00
SEPT Mid Target
$16.00
SEPT High Target
$16.00
Analyst Consensus
$16.00
Is XLO a Buy or Sell Right Now?
Thesis
- •Revenue growing 589.9% YoY with UNKNOWN trend — consistent growth.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for XLO.
Start Free Trial →Is XLO Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
Analyst Consensus
Fair Value
$16.00
0
Moat Score
NONE
4/9
Piotroski Score
-3.3
Altman Z-Score
What Is Smart Money Doing with XLO?
Insider Signal
NEUTRAL
1 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →XLO Growth Story
Revenue YoY
589.9%
3yr Revenue CAGR
N/A%
EPS Growth YoY
72.51%
FCF Growth YoY
70.1%
Revenue Trend
UNKNOWN
Dark Pool Trades for XLO
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for XLO, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 20:13:32 | $8.13 | 1,001 | $$8K | SELL |
| 15:58:08 | $7.96 | 1,649 | $$13K | SELL |
| 20:15:00 | $8.20 | 1,000 | $$8K | SELL |
| 19:34:20 | $8.61 | 1,500 | $$13K | BUY |
| 16:29:43 | $8.48 | 1,000 | $$8K | MIDPOINT |
5 dark pool trades shown · $$51K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Xilio Therapeutics, Inc. (XLO) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (3 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →XLO — frequently asked questions
What is XLO stock price today?
Xilio Therapeutics, Inc. (XLO) is at $8.24, down 2.72% (-$0.23) at the Nov 12, 2026 close.
Why is XLO stock moving today?
Latest XLO news — Nov 10, 2026: Xilio Therapeutics Posts Q3 2026 Results, Gives Pipeline Update · Nov 10, 2026: Xilio Therapeutics posts smaller Q3 loss, revenue above estimates
Why did XLO stock move on Nov 10, 2026?
Xilio Therapeutics reported Q3 2026 results, posting a narrower-than-expected loss of $0.30 per share versus the $0.82 loss analysts anticipated, while revenue of $9.984 million came in well above the $4.840 million estimate. The company also provided a pipeline update and filed a Form 8-K disclosing a major company event.
What is the XLO price target?
The average analyst price target for XLO is $16.00, ranging from $16 to $16, based on 1 analysts. Latest: Raymond James initiates on Oct 21, 2026.
What do analysts rate XLO?
Analyst ratings for XLO: 0 Buy, 2 Hold, 0 Sell — consensus Hold.
Did XLO beat earnings?
XLO last reported on Nov 12, 2026: EPS -$0.30 vs -$0.82 expected — a beat of 63.4%.
Does XLO pay a dividend?
XLO does not currently pay a dividend.
What are XLO support and resistance levels?
Support: $7.05. Resistance: $8.33, $9.00, $9.67.
What are insiders doing with XLO?
Insider activity: NEUTRAL, 1 buys and 0 sells in the last 90 days.
What is the latest news on XLO?
Nov 10, 2026: Xilio Therapeutics Posts Q3 2026 Results, Gives Pipeline Update · Nov 10, 2026: Xilio Therapeutics posts smaller Q3 loss, revenue above estimates · Nov 10, 2026: Xilio Therapeutics, Inc. filed a report on a major company event (Form 8-K)